Links:

<https://mushroomprotocol.io/>

<https://www.linkedin.com/company/mushroom-protocol/posts/?feedView=all>

<https://x.com/MushromProtocol>

<https://discord.com/invite/wxe4aMwZWT>

Bio:

For the past 20 years, investment in R&D—especially in biotechnology—has remained stagnant in Latin America.

While developed countries allocate over 3% of their GDP to R&D (with 70% coming from private sources), Latin American countries invest an average of just 0.5%, with 60% of funding coming from public institutions.

So its pretty obvious that we need to increase the private investment but there are high entry barrieres that keep investors away: high capital requirements, long time horizons, complex regulations, lack of market knowledge, and the traditionally low liquidity of biotech investments.

At Mushroom, we are breaking down these barriers. Our platform enables retail, traditional, and private investors to access biotech opportunities in a fractional, simple, and liquid way.

Using blockchain, we tokenize two key asset classes:

🔹 Intellectual Property from early-stage research

🔹 Equity in biotech startups

This allows investors worldwide to participate in the ownership of cutting-edge biotechnologies from their earliest stages.

Mushroom is the only platform in Latin America that enables investment in both biotech research and early-stage startups. We bridge the funding gap for university researchers and science-driven entrepreneurs, providing the capital they need to transform their discoveries into real-world innovations.

By democratizing access to biotech investment, we are transforming the industry from both sides:

✅ Investors gain access to affordable, simple, and liquid biotech opportunities.

✅ Researchers and startups secure early funding to turn scientific breakthroughs into impactful solutions.

Mushroom is not just a platform—it’s a catalyst for biotech innovation in Latin America.